|
1
|
Bermudez O, Pages G and Gimond C: The
dual-specificity MAP kinase phosphatases: Critical roles in
development and cancer. Am J Physiol Cell Physiol. 299:C189–C202.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wei W, Jiao Y, Postlethwaite A, Stuart JM,
Wang Y, Sun D and Gu W: Dual-specificity phosphatases 2: Surprising
positive effect at the molecular level and a potential biomarker of
diseases. Genes Immun. 14:1–6. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hamamura K, Nishimura A, Chen A, Takigawa
S, Sudo A and Yokota H: Salubrinal acts as a Dusp2 inhibitor and
suppresses inflammation in anti-collagen antibody-induced
arthritis. Cellular signalling. 27:828–835. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Perander M, Al-Mahdi R, Jensen TC, Nunn
JA, Kildalsen H, Johansen B, Gabrielsen M, Keyse SM and Seternes
OM: Regulation of atypical MAP kinases ERK3 and ERK4 by the
phosphatase DUSP2. Sci Rep. 7:434712017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yin Y, Liu YX, Jin YJ, Hall EJ and Barrett
JC: PAC1 phosphatase is a transcription target of p53 in signalling
apoptosis and growth suppression. Nature. 422:527–531. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Haag T, Richter AM, Schneider MB, Jimenez
AP and Dammann RH: The dual specificity phosphatase 2 gene is
hypermethylated in human cancer and regulated by epigenetic
mechanisms. BMC Cancer. 16:492016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin SC, Chien CW, Lee JC, Yeh YC, Hsu KF,
Lai YY, Lin SC and Tsai SJ: Suppression of dual-specificity
phosphatase-2 by hypoxia increases chemoresistance and malignancy
in human cancer cells. J Clin Invest. 121:1905–1916. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee YH, Morrison BL and Bottaro DP:
Synergistic signaling of tumor cell invasiveness by hepatocyte
growth factor and hypoxia. J Biol Chem. 289:20448–20461. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Karakashev SV and Reginato MJ:
Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast
cancer cells via regulation of DUSP2. Oncotarget. 6:1967–1980.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hou PC, Li YH, Lin SC, Lin SC, Lee JC, Lin
BW, Liou JP, Chang JY, Kuo CC, Liu YM, et al: Hypoxia-Induced
downregulation of DUSP-2 phosphatase drives colon cancer stemness.
Cancer Res. 77:4305–4316. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin SC, Hsiao KY, Chang N, Hou PC and Tsai
SJ: Loss of dual-specificity phosphatase-2 promotes angiogenesis
and metastasis via up-regulation of interleukin-8 in colon cancer.
J Pathol. 241:638–648. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Givant-Horwitz V, Davidson B, Goderstad
JM, Nesland JM, Tropé CG and Reich R: The PAC-1 dual specificity
phosphatase predicts poor outcome in serous ovarian carcinoma.
Gynecol Oncol. 93:517–523. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhu W, Huang L, Xu X, Qian H and Xu W:
Anti-proliferation effect of BMI-1 in U937 cells with siRNA. Int J
Mol Med. 25:889–895. 2010.PubMed/NCBI
|
|
14
|
Wang XF, Zhao YB, Wu Q, Sun ZH and Li HJ:
Triptolide induces apoptosis in endometrial cancer via a p53
independent mitochondrial pathway. Mol Med Rep. 9:39–44. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Trastour C, Benizri E, Ettore F, Ramaioli
A, Chamorey E, Pouysségur J and Berra E: HIF-1alpha and CA IX
staining in invasive breast carcinomas: Prognosis and treatment
outcome. Int J Cancer. 120:1451–1458. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tashiro E, Henmi S, Odake H, Ino S and
Imoto M: Involvement of the MEK/ERK pathway in EGF-induced
E-cadherin down-regulation. Biochem Biophys Res Commun.
477:801–806. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Boeckx C, Op de Beeck K, Wouters A,
Deschoolmeester V, Limame R, Zwaenepoel K, Specenier P, Pauwels P,
Vermorken JB, Peeters M, et al: Overcoming cetuximab resistance in
HNSCC: The role of AURKB and DUSP proteins. Cancer Lett.
354:365–377. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Y, Huang Y, Hou P, Zhang Z, Zhang Y,
Wang W, Sun G, Xu L, Zhou J, Bai J and Zheng J: ING4 suppresses
tumor angiogenesis and functions as a prognostic marker in human
colorectal cancer. Oncotarget. 7:79017–79031. 2016.PubMed/NCBI
|
|
19
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang X, Song Y, Song N, Zhang Y, Zhang L,
Wang Y, Wang Z, Qu X and Liu Y: RANKL/RANK pathway abrogates
cetuximab sensitivity in gastric cancer cells via activation of
EGFR and c-Src. Onco Targets Ther. 10:73–83. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Taieb J, Balogoun R, Le Malicot K,
Tabernero J, Mini E, Folprecht G, Van Laethem JL, Emile JF, Mulot
C, Fratté S, et al: Adjuvant FOLFOX +/−cetuximab in full RAS and
BRAF wildtype stage III colon cancer patients. Ann Oncol.
28:824–830. 2017.PubMed/NCBI
|
|
22
|
Queralt B, Cuyàs E, Bosch-Barrera J,
Massaguer A, de Llorens R, Martin-Castillo B, Brunet J, Salazar R
and Menendez JA: Synthetic lethal interaction of cetuximab with
MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Oncotarget. 7:82185–82199. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang F, Bai L, Liu TS, Yu YY, He MM, Liu
KY, Luo HY, Zhang DS, Jin Y, Wang FH, et al: Right-sided colon
cancer and left-sided colorectal cancers respond differently to
cetuximab. Chin J Cancer. 34:384–393. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brule SY, Jonker DJ, Karapetis CS,
O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D,
Zalcberg JR, et al: Location of colon cancer (right-sided versus
left-sided) as a prognostic factor and a predictor of benefit from
cetuximab in NCIC CO.17. Eur J Cancer. 51:1405–1414. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moretto R, Cremolini C, Rossini D,
Pietrantonio F, Battaglin F, Mennitto A, Bergamo F, Loupakis F,
Marmorino F, Berenato R, et al: Location of primary tumor and
benefit from anti-epidermal growth factor receptor monoclonal
antibodies in patients with RAS and BRAF wild-type metastatic
colorectal cancer. Oncologist. 21:988–994. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dienstmann R, Vermeulen L, Guinney J,
Kopetz S, Tejpar S and Tabernero J: Consensus molecular subtypes
and the evolution of precision medicine in colorectal cancer. Nat
Rev. 17:79–92. 2017. View Article : Google Scholar
|
|
27
|
Zhu H, Wu TC, Chen WQ, Zhou LJ, Wu Y, Zeng
L and Pei HP: Screening for differentially expressed genes between
left- and right-sided colon carcinoma by microarray analysis. Oncol
Lett. 6:353–358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Joo D, Woo JS, Cho KH, Han SH, Min TS,
Yang DC and Yun CH: Biphasic activation of extracellular
signal-regulated kinase (ERK)1/2 in epidermal growth factor
(EGF)-stimulated SW480 colorectal cancer cells. BMB Rep.
49:220–225. 2016. View Article : Google Scholar : PubMed/NCBI
|
